Nathan B. Fountain net worth and biography

Nathan Fountain Biography and Net Worth

Director of Acumen Pharmaceuticals

Dr. Fountain has served as a member of our board of directors since June2021. Dr. Fountain is Professor of Neurology at the University of Virginia School of Medicine and has served as Director of the F.E. Dreifuss Comprehensive Program since 1998. Dr. Fountain serves as a consultant to a number of companies, including Sands Capital. Dr. Fountain is the founding co-chair of the Epilepsy Foundation’s Research Roundtable for Epilepsy. Dr. Fountain is immediate past-president of the National Association of Epilepsy Centers where he remains on the board of directors ex officio. Dr. Fountain served on the FDA Peripheral and CNS Drugs Advisory Committee from November 2010 to June 2021, most recently serving as chair of the committee from February 2018 through June 2021. Dr. Fountain has been the chair of the Professional Advisory Board for the Epilepsy Foundation of Virginia since 2009. Dr. Fountain received an M.D. from the University of Iowa College of Medicine and a B.S. in Zoology from the University of Iowa.

How do I contact Nathan B. Fountain?: The corporate mailing address for Dr. Fountain and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at investors@acumenpharm.com. Learn More on Nathan B. Fountain's contact information.
Has Nathan B. Fountain been buying or selling shares of Acumen Pharmaceuticals?: Nathan B. Fountain has not been actively trading shares of Acumen Pharmaceuticals during the last ninety days. Learn More on Nathan B. Fountain's trading history.
Who are Acumen Pharmaceuticals' active insiders?: Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Acumen Pharmaceuticals?: During the last year, insiders at the sold shares 9 times. They sold a total of 131,526 shares worth more than $233,123.83. The most recent insider tranaction occured on January, 23rd when CFO Matt Zuga sold 28,902 shares worth more than $49,711.44. Insiders at Acumen Pharmaceuticals own 7.1% of the company. Learn More about insider trades at Acumen Pharmaceuticals.
Information on this page was last updated on 1/23/2025.

Nathan B. Fountain Insider Trading History at Acumen Pharmaceuticals

Nathan B. Fountain Buying and Selling Activity at Acumen Pharmaceuticals

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Today's Range

Now: $1.19

$1.15

$1.25

50 Day Range

MA: $1.38

$1.15

$1.75

2 Week Range

Now: $1.19

$1.10

$4.06

Volume

118,755 shs

Average Volume

288,822 shs

Market Capitalization

$71.50 million

P/E Ratio

N/A

Dividend Yield